FindTrial
Sign In

A STUDY ON DISEASE PROGRESSION AND OUTCOME WITH THE TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

A STUDY ON LUPUS LOW DISEASE ACTVITY STATE AND ITS SIGNIFICANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/033969
Enrollment
167
Registered
2021-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M32- Systemic lupus erythematosus (SLE)

Interventions

None listed

Sponsors

KASTURBA HOSPITAL MANIPAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients newly diagnosed with SLE. Patients already diagnosed with SLE and on treatment. Patients with follow up visits with a maximum 6 month limit. Age more than 18

Exclusion criteria

Exclusion criteria: Patients without at least one follow-up. Patients with other autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
SLEDAI score and PGA are assessed for LLDAS. Sledai score assessment includes clinical and lab investigations and PGA score includes overall general assessment by physician and the outcome of the two including with ongoing treatment thereby assessing the severity of the disease activity.Timepoint: At base line.—

Secondary

MeasureTime frame
the study helps in assessing the treatment and need for control of flaresTimepoint: At discharge,After 6 weeks.—

Countries

India

Contacts

Public ContactDR RAJASHEKAR REDDY

Kasturba Medical College, Kasturba Hospital, Manipal

ram.bhat@manipal.edu9945272251

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026